<DOC>
	<DOCNO>NCT01148225</DOCNO>
	<brief_summary>There unmet medical need non-infectious intermediate- , posterior- pan uveitis . These type uveitis high risk vision loss compare anterior uveitis . Patients types uveitis often treat chronic corticosteroid . The use chronic corticosteroid link predictable long-term side effect . The objective study evaluate long term efficacy safety adalimumab subject non-infectious intermediate- , posterior- pan-uveitis .</brief_summary>
	<brief_title>A Study Long-term Safety Efficacy Adalimumab Subjects With Intermediate- , Posterior- , Pan-uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must successfully enrol either study M10877 M10880 either meet endpoint `` Treatment Failure '' complete study A subject exclude study patient discontinue study M10877 M10880 reason Treatment Failure event Subject corneal lens opacity precludes visualization fundus likely require cataract surgery duration trial Subjects intraocular pressure &gt; = 25 mmHg &gt; = 2 glaucoma medication evidence glaucomatous optic nerve injury Subject proliferative severe nonproliferative diabetic retinopathy clinically significant macular edema due diabetic retinopathy Subject neovascular/wet agerelated macular degeneration Subject abnormality vitreoretinal interface ( i.e. , vitreomacular traction , epiretinal membrane , etc . ) potential macular structural damage independent inflammatory process Subject systemic inflammatory disease require therapy prohibit immunosuppressive agent time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-infectious Uveitis</keyword>
	<keyword>Active Uveitis</keyword>
	<keyword>Posterior-Uveitis</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Pan-uveitis</keyword>
	<keyword>Intermediate-Uveitis</keyword>
</DOC>